COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment
Immune-modifying treatment in inflammatory bowel disease (IBD) impairs the humoral response. The role of T lymphocytes in this setting is still unclear. This study aims to assess if a booster shot (third dose) of BNT162b2 mRNA COVID-19 vaccine enhanced the humoral response and elicited cellular immu...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/3/591 |
| _version_ | 1797608688962240512 |
|---|---|
| author | Grazia Pavia Rocco Spagnuolo Angela Quirino Nadia Marascio Aida Giancotti Silvio Simeone Cristina Cosco Elena Tino Federico Carrabetta Gianfranco Di Gennaro Carmelo Nobile Aida Bianco Giovanni Matera Patrizia Doldo |
| author_facet | Grazia Pavia Rocco Spagnuolo Angela Quirino Nadia Marascio Aida Giancotti Silvio Simeone Cristina Cosco Elena Tino Federico Carrabetta Gianfranco Di Gennaro Carmelo Nobile Aida Bianco Giovanni Matera Patrizia Doldo |
| author_sort | Grazia Pavia |
| collection | DOAJ |
| description | Immune-modifying treatment in inflammatory bowel disease (IBD) impairs the humoral response. The role of T lymphocytes in this setting is still unclear. This study aims to assess if a booster shot (third dose) of BNT162b2 mRNA COVID-19 vaccine enhanced the humoral response and elicited cellular immunity in IBD patients on different immuno-therapy regimens compared to healthy controls (HCs). Five months after a booster dose, serological and T-cell responses were assessed. The measurements were described using geometric means with 95% confidence intervals. The differences between study groups were assessed by Mann–Whitney tests. Seventy-seven subjects (<i>n</i> = 53 IBD patients and <i>n</i> = 24 HCs), who were fully vaccinated and not previously SARS-CoV-2 infected, were recruited. Regarding the IBD patients, 19 were affected by Crohn’s disease and 34 by ulcerative colitis. During the vaccination cycle, half of the patients (53%) were on stable treatment with aminosalicylates, and 32% were on biological therapy. No differences in antibody concentrations between IBD patients and HCs, nor T-cell responses, were found. Stratifying IBD patients based on the type of treatment (anti-TNFα agents vs. other treatment regimens), a decrease only in antibody titer (<i>p</i> = 0.008), but not in cellular response, was observed. Even after the COVID-19 vaccine booster dose, the TNFα inhibitors selectively decreased the humoral immune response compared to patients on other treatment regimens. The T-cell response was preserved in all study groups. These findings highlight the importance of evaluating T-cell immune responses following COVID-19 vaccination in a routine diagnostic setting, particularly for immunocompromised cohorts. |
| first_indexed | 2024-03-11T05:48:09Z |
| format | Article |
| id | doaj.art-6073daf441de4f63bf25dc8d7a1699a8 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T05:48:09Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-6073daf441de4f63bf25dc8d7a1699a82023-11-17T14:18:13ZengMDPI AGVaccines2076-393X2023-03-0111359110.3390/vaccines11030591COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα TreatmentGrazia Pavia0Rocco Spagnuolo1Angela Quirino2Nadia Marascio3Aida Giancotti4Silvio Simeone5Cristina Cosco6Elena Tino7Federico Carrabetta8Gianfranco Di Gennaro9Carmelo Nobile10Aida Bianco11Giovanni Matera12Patrizia Doldo13Unit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyDepartment of Health Sciences, School of Medicine, “Magna Græcia” University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, School of Medicine, “Magna Græcia” University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, School of Medicine, “Magna Græcia” University of Catanzaro, 88100 Catanzaro, ItalyUnit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyUnit of Gastroenterology, Department of Clinical and Experimental Medicine, “Magna Græcia” University of Catanzaro—“Mater Domini” Teaching Hospital, 88100 Catanzaro, ItalyImmune-modifying treatment in inflammatory bowel disease (IBD) impairs the humoral response. The role of T lymphocytes in this setting is still unclear. This study aims to assess if a booster shot (third dose) of BNT162b2 mRNA COVID-19 vaccine enhanced the humoral response and elicited cellular immunity in IBD patients on different immuno-therapy regimens compared to healthy controls (HCs). Five months after a booster dose, serological and T-cell responses were assessed. The measurements were described using geometric means with 95% confidence intervals. The differences between study groups were assessed by Mann–Whitney tests. Seventy-seven subjects (<i>n</i> = 53 IBD patients and <i>n</i> = 24 HCs), who were fully vaccinated and not previously SARS-CoV-2 infected, were recruited. Regarding the IBD patients, 19 were affected by Crohn’s disease and 34 by ulcerative colitis. During the vaccination cycle, half of the patients (53%) were on stable treatment with aminosalicylates, and 32% were on biological therapy. No differences in antibody concentrations between IBD patients and HCs, nor T-cell responses, were found. Stratifying IBD patients based on the type of treatment (anti-TNFα agents vs. other treatment regimens), a decrease only in antibody titer (<i>p</i> = 0.008), but not in cellular response, was observed. Even after the COVID-19 vaccine booster dose, the TNFα inhibitors selectively decreased the humoral immune response compared to patients on other treatment regimens. The T-cell response was preserved in all study groups. These findings highlight the importance of evaluating T-cell immune responses following COVID-19 vaccination in a routine diagnostic setting, particularly for immunocompromised cohorts.https://www.mdpi.com/2076-393X/11/3/591cellular immune responsehumoral immune responseanti-SARS-CoV-2 immunogenicityinflammatory bowel diseaseanti-TNFα agents |
| spellingShingle | Grazia Pavia Rocco Spagnuolo Angela Quirino Nadia Marascio Aida Giancotti Silvio Simeone Cristina Cosco Elena Tino Federico Carrabetta Gianfranco Di Gennaro Carmelo Nobile Aida Bianco Giovanni Matera Patrizia Doldo COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment Vaccines cellular immune response humoral immune response anti-SARS-CoV-2 immunogenicity inflammatory bowel disease anti-TNFα agents |
| title | COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment |
| title_full | COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment |
| title_fullStr | COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment |
| title_full_unstemmed | COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment |
| title_short | COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment |
| title_sort | covid 19 vaccine booster shot preserves t cells immune response based on interferon gamma release assay in inflammatory bowel disease ibd patients on anti tnfα treatment |
| topic | cellular immune response humoral immune response anti-SARS-CoV-2 immunogenicity inflammatory bowel disease anti-TNFα agents |
| url | https://www.mdpi.com/2076-393X/11/3/591 |
| work_keys_str_mv | AT graziapavia covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT roccospagnuolo covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT angelaquirino covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT nadiamarascio covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT aidagiancotti covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT silviosimeone covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT cristinacosco covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT elenatino covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT federicocarrabetta covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT gianfrancodigennaro covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT carmelonobile covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT aidabianco covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT giovannimatera covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment AT patriziadoldo covid19vaccineboostershotpreservestcellsimmuneresponsebasedoninterferongammareleaseassayininflammatoryboweldiseaseibdpatientsonantitnfatreatment |